<DOC>
	<DOCNO>NCT01205373</DOCNO>
	<brief_summary>The main objective present study investigate basic pharmacokinetics BI 671800 , major metabolite CD6384 , 14C-radioactivity , include mass balance , excretion pathway metabolism follow single oral dose 400 mg [ 14C ] BI 671800 HEA healthy male volunteer . Secondary objective evaluate safety tolerability follow single oral dose 400 mg [ 14C ] BI 671800 HEA healthy male volunteer .</brief_summary>
	<brief_title>A Phase I Trial Investigate Metabolism Pharmacokinetics Well Safety Tolerability Single Dose BI671800 HEA Administered Oral Solution Choline Salt Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Choline</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male accord complete medical history , include physical examination ( perform Day 1 ) , vital sign ( blood pressure , pulse rate ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test 2 . Age 18 55 year , inclusive 3 . Body mass index 18.0 30.0 kg/m2 , inclusive 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : 1 . Any finding medical examination ( include blood pressure , pulse rate , ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . History relevant orthostatic hypotension , faint spell , blackouts 6 . Chronic relevant acute infection 7 . History relevant allergy/hypersensitivity ( include allergy study drug excipients ) 8 . Use prescription drug 30 day prior screen . 9 . Use overthecounter , nonprescription preparation ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ) within 7 day prior Checkin , unless deem acceptable Investigator 10 . Participation another trial investigational drug within 2 month prior administration trial 11 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) positive urine cotinine test screening checkin ( Day 1 ) 12 . Inability refrain smoke stay trial centre 13 . Alcohol abuse ( average 2 unit alcoholic beverage per day 14 unit per week . One unit equal 1 pint ( 285 mL ) beer lager , 1 glass ( 125 mL ) wine , one shot ( 25 mL ) 40 % spirit , positive urine alcohol test screening checkin ( Day 1 ) 14 . Drug abuse 15 . Blood donation ( &gt; 100 mL within 60 day prior study drug administration trial ) 16 . Excessive physical activity ( within 1 week prior administration trial followup examination ) 17 . Any laboratory value outside reference range clinical relevance accord investigator 18 . Inability comply dietary regimen study centre 19 . A marked baseline prolongation QT QTc interval , history additional risk factor torsade de pointes ( e.g . heart failure , hypokalaemia , family history long QT syndrome ) 20 . Veins unsuitable blood sample 21 . Exposure diagnostic radiation occupational reason participation clinical trial previous year ( except dental Xrays plain Xrays thorax bony skeleton [ exclude spinal column ] ) 22 . Irregular defecation pattern ( less per day ) 23 . Unwillingness use adequate contraception ( condom plus another form contraception e.g . spermicide , oral contraceptive take female partner , sterilisation , intrauterine device ) entire study time first intake study drug 3 month last intake 24 . Any laboratory value outside reference range clinical relevance , especially repeat Alanine transaminase ( ALT ) , Aspartate transaminase ( AST ) , Gammaglutamyltransferase ( GGT ) , alkaline phosphatase , total bilirubin upper limit normal screen resolve dose 25 . Use drug might reasonably influence result trial prolong QT/QTc interval within 10 day prior administration trial , Cytochrome P450 ( CYP ) 2C8 substrate amiodarone , amodiaquine , paclitaxel , rosiglitazone , pioglitazone repaglinide CYP2C9 warfarin , tolbutamide , phenytoin , losartan , acenocoumarol within 1 month six half life ( whichever great )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>